Research Topics
Species | Howard SafranSummaryAffiliation: Rhode Island Hospital Country: USA Publications
| Collaborators
|
Detail Information
Publications
Paclitaxel, cisplatin, and concurrent radiation for esophageal cancerH Safran
Brown University Oncology Group, Providence, Rhode Island
Cancer Invest 19:1-7. 2001..Esophagitis was less severe than expected and prophylactic enteral feeding tubes were not necessary. Additional effective systemic treatments are needed to reduce the development of distant metastases...- Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicityHoward Safran
Brown University Oncology Group, Providence, RI, USA
Int J Radiat Oncol Biol Phys 70:391-5. 2008..To determine the feasibility and toxicity of the addition of cetuximab with paclitaxel, carboplatin, and radiation for patients with esophagogastric cancer on a Phase II study... 
Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancerHoward Safran
Department of Medicine, The Miriam Hospital, Brown University Oncology Group, Providence, Rhode Island 02906, USA
Am J Clin Oncol 31:140-4. 2008..To evaluate the safety/tolerability and potential antitumor activity of lapatinib, at dose ranges of 1000 to 1500 mg/d, in combination with gemcitabine and gemcitabine/oxaliplatin (GEMOX) in patients with advanced pancreaticobiliary cancer...- Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I studyHoward Safran
The Brown University Oncology Group, Providence, Rhode Island, USA
Cancer Invest 22:670-7. 2004..To conduct a phase I study incorporating trastuzumab with paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus... - Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a Phase I trialHoward Safran
The Brown University Oncology Group, Department of Medicine, The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906, USA
Int J Radiat Oncol Biol Phys 54:137-41. 2002..To determine the maximum tolerated dose (MTD) and dose-limiting toxicities of gemcitabine, paclitaxel, and concurrent radiation for pancreatic cancer... - Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neuHoward Safran
The Brown University Oncology Group, Providence, Rhode Island, USA
Cancer Invest 22:706-12. 2004..To determine the response rate and toxicities of Herceptin and gemcitabine for patients with metastatic pancreatic adenocarcinomas that overexpress HER-2/neu... - Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinomaHoward Safran
Brown University Oncology Group, Providence, RI, USA
Int J Radiat Oncol Biol Phys 67:405-9. 2007..To determine the overall survival for patients with locally advanced, HER2 overexpressing, esophageal adenocarcinoma receiving trastuzumab, paclitaxel, cisplatin, and radiation on a Phase I-II study... - Paclitaxel as a radiation sensitizer for locally advanced pancreatic cancerHoward Safran
The Brown University Oncology Group, Department of Medicine, The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906, USA
Crit Rev Oncol Hematol 43:57-62. 2002..The addition of gemcitabine to paclitaxel and radiation has also demonstrated promising preliminary activity and a phase II study by the RTOG is being initiated... - HER family inhibitors in pancreatic cancer: current status and future directionsDavid Berz
The Brown University Oncology Group, 164 Summit Avenue, Providence, RI 02906, USA
Expert Opin Ther Targets 11:337-47. 2007..This article reviews clinical trials of HER family inhibitors in pancreatic cancer, discusses the role of these agents in the management of patients and outlines future directions for pancreatic cancer management... - Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancerJames Y Tsai
Brown University Oncology Group, Providence, Rhode Island, USA
Am J Clin Oncol 28:329-33. 2005..This combination represents an easily administered, active regimen for patients with metastatic gastric and esophageal cancers. Further evaluation of this regimen is indicated... - Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: a phase II studyDevon Evans
The Brown University Oncology Group, Providence, Rhode Island 02906, USA
Cancer Invest 25:445-8. 2007..The objectives of this Phase II study were to determine the response rate, toxicity, and survival for patients with metastatic esophagogastric cancer treated with this regimen... - Paclitaxel poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: a phase I studyTom Dipetrillo
Brown University Oncology Group, Providence, RI, USA
Am J Clin Oncol 29:376-9. 2006..Four of 12 patients (33%) with loco-regional disease had a complete clinical response. CONCLUSIONS: The maximally tolerated dose of PPX with concurrent radiotherapy is 70 mg/m2/wk for patients with esophageal and gastric cancer... - Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I studyDavid Iannitti
Brown University Oncology Group, Providence, RI, USA
Am J Clin Oncol 28:570-5. 2005..Full dose maintenance erlotinib is well tolerated. Promising preliminary activity and overall survival were demonstrated... - Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: a phase 2 trialThomas DiPetrillo
The Brown University Oncology Group, Providence, Rhode Island, USA
Am J Clin Oncol 35:64-7. 2012..To evaluate the pathologic complete response (CR) rate and safety of paclitaxel poliglumex (PPX), cisplatin, and concurrent radiation for patients with esophageal cancer... - A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancerDevon Evans
Brown University Oncology Group, Providence, RI, USA
Am J Clin Oncol 30:346-9. 2007..The Brown University Oncology Group initiated a phase I study to determine the maximum tolerated dose of weekly docetaxel, oxaliplatin, and capecitabine... - Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancerTom Dipetrillo
Brown University Oncology Group, Providence, RI 02906, USA
Int J Radiat Oncol Biol Phys 82:124-9. 2012.... - Phase I study of hepatic arterial infusion of oxaliplatin in advanced hepatocellular cancer: a brown university oncology group studyRitesh Rathore
Division of Hematology Oncology, Roger Williams Hospital, Providence, Rhode Island 02908, USA
Am J Clin Oncol 33:43-6. 2010..We performed a phase I study to evaluate the feasibility and determine the maximally tolerated dose of hepatic arterial infusion (HAI) of oxaliplatin in advanced hepatocellular carcinoma (HCC)... - Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysisAriel Birnbaum
Brown University Oncology Group, Providence RI, USA
Am J Clin Oncol 33:144-7. 2010..To determine the feasibility and toxicity of the addition of cetuximab to paclitaxel, carboplatin, and concurrent radiation for patients with head and neck cancer... - Paclitaxel and concurrent radiation in upper gastrointestinal cancersMaria Constantinou
Brown University Oncology Group, Providence, Rhode Island, USA
Cancer Invest 21:887-96. 2003..Ongoing trials in pancreatic cancer are investigating the addition of gemcitabine to paclitaxel and radiation and incorporating molecular targeting agents... - Multimodality treatment of esophageal cancer: a review of the current status and future directionsThomas Ng
Department of Medicine, The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906, USA
Curr Oncol Rep 8:174-82. 2006..Advances in radiation oncology and surgery may decrease morbidity and mortality from trimodality therapy, improving patient outcome... - Chemotherapy for pancreatic cancerJames Y Tsai
Department of Medicine, Brown Medical School, USA
Med Health R I 87:132-4. 2004 - A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinomaWallace Akerley
Department of Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, USA
Cancer 95:2000-5. 2002..We conducted a Phase I study of weekly paclitaxel (P) and carboplatin (C) in patients with advanced malignancies to determine the maximum tolerated dose (MTD) of this combination... 
A Phase I Study of Dasatinib with Concurrent Chemoradiation for Stage III Non-Small Cell Lung CancerHumera Khurshid
The Brown University Oncology Group, Providence RI, USA
Front Oncol 2:56. 2012..Due to these toxicities the Brown University Oncology Group Data Safety Monitoring Board terminated the study. Conclusion: Dasatinib could not be safely combined with concurrent chemoradiation for stage 3 lung cancer due to pneumonitis...- Combined modality therapy for pancreatic cancerJames Y Tsai
Brown University Oncology Group, Providence, RI, USA
Semin Oncol 30:71-9. 2003..Molecular agents are being combined with chemoradiation in an attempt to delay or prevent systemic progression... - Tumor progression-related transmembrane protein aspartate-β-hydroxylase is a target for immunotherapy of hepatocellular carcinomaMasafumi Shimoda
The Warren Alpert Medical School of Brown University, Providence, RI, USA
J Hepatol 56:1129-35. 2012.... - Status of treatment for advanced gastric carcinomaJames Y Tsai
Department of Medicine, The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906, USA
Curr Oncol Rep 5:210-8. 2003..It is anticipated that the development of these active new agents will ultimately improve survival for patients with advanced gastric cancer... - Human aspartyl (asparaginyl) beta-hydroxylase monoclonal antibodies: potential biomarkers for pancreatic carcinomaKevin S Palumbo
Department of Medicine, Rhode Island Hospital, Brown University School of Medicine, Providence, Rhode Island 02903, USA
Pancreas 25:39-44. 2002.... - Evaluation and treatment of hepatic metastases from unknown GI primaryNadia Ramdin
Department of Hematology/Oncology, The Miriam Hospital, 168 Summit Ave, Providence, RI 02908, USA
Med Health R I 85:181-3. 2002 - Dosimetric Feasibility of Dose Escalation Using SBRT Boost for Stage III Non-Small Cell Lung CancerJaroslaw T Hepel
Department of Radiation Oncology, Rhode Island Hospital, Brown University Providence, RI, USA
Front Oncol 2:124. 2012..A phase I/II trial to evaluate the clinical safety and efficacy of this approach is being undertaken... - Percutaneous radiofrequency ablation of painful osseous metastases: a multicenter American College of Radiology Imaging Network trialDamian E Dupuy
Department of Diagnostic Imaging, The Warren Alpert Medical School at Brown University, Providence, RI 02903, USA
Cancer 116:989-97. 2010..The study was conducted to determine whether radiofrequency ablation (RFA) can safely reduce pain from osseous metastatic disease... - ErbB2 degradation mediated by the co-chaperone protein CHIPPengcheng Zhou
Division of Rheumatology, Immunology, and Allergy, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
J Biol Chem 278:13829-37. 2003.... - Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trialWilliam F Regine
Department of Radiation Oncology, University of Maryland Medical Center, Baltimore 21030, USA
JAMA 299:1019-26. 2008..Among patients with locally advanced metastatic pancreatic adenocarcinoma, gemcitabine has been shown to improve outcomes compared with fluorouracil... - Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trialsChristopher G Willett
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
Int J Radiat Oncol Biol Phys 56:31-7. 2003..This report summarizes current and future Radiation Therapy Oncology Group clinical trials in the treatment of patients with localized pancreatic cancer... - Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trialRamesh K Ramanathan
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15232, USA
Cancer Invest 22:858-65. 2004.... - Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancerWallace Akerley
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84115, USA
Cancer 107:1050-4. 2006..The purpose of the current study was to evaluate the efficacy and tolerance of the noncisplatin-based combination of paclitaxel and gemcitabine administered weekly for patients with untreated metastatic nonsmall cell lung cancer (NSCLC)... - A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving boneWallace Akerley
Boston University Medical Center, Oncology Hematology, Boston, Massachusetts 02118, USA
Cancer 94:1654-60. 2002..2 MBq/kg on Day 1. Courses were repeated every 12 weeks. Response assessment was based on a change in the serum prostate specific antigen (PSA) levels, correlated with change in measurable disease and bone scan appearance...